IPP Bureau
Themis gets DCGI approval of Remifentanil Hydrochloride 1mg/2mg injection for import and marketing
By IPP Bureau - February 18, 2023
Themis will market this drug with the brand name REMITHEM.
AstraZeneca Pharma India receives no objection for Durvalumab
By IPP Bureau - February 17, 2023
Durvalumab in combination with chemotherapy is indicated for the treatment of patients with locally advanced or metastatic biliary tract cancer
Biocon Q3 FY23 revenue up 36%
By IPP Bureau - February 17, 2023
The company's consolidated revenues for the quarter grew 36% to Rs. 3,020 crore on the back of robust performance across all its three businesses
Moderna’s non-vaccine mRNA therapeutic set to generate $278 million in 2028 if approved, estimates GlobalData
By IPP Bureau - February 17, 2023
According to GlobalData’s analyst consensus forecast, OTX-2002 is projected to have the highest revenue by 2028, with sales of $1.6 billion during that year
GUERISON enters Indian Ophthalmology market
By IPP Bureau - February 17, 2023
The company has launched its new range of 25 allopathy ophthalmic products including GUERIMOD, GUERIPRED, BIMATO MST etc. for curing various diseases related to eyes
Briefs: Piramal Pharma, Alembic Pharmaceuticals
By IPP Bureau - February 17, 2023
USFDA has issued an Establishment Inspection Report (EIR) for Piramal Pharma Limited manufacturing facility located at Lexington (Kentucky, USA) and the inspection has now been successfully closed by the USFDA
Shilpa Medicare Unit VI Bengaluru facility registered with Ministry of Health, UAE
By IPP Bureau - February 17, 2023
This registration enables companies to register the products (Orodispersible films and Transdermal systems) in UAE for commercialization
Lonza completes expansion of conjugation facility in Visp
By IPP Bureau - February 17, 2023
The investment enhances Lonza’s capabilities and flexibility to support both clinical and commercial supply and will play a key role in meeting the growing market demand for bioconjugates
Zydus receives tentative approval from USFDA for Bosentan tablets for oral suspension
By IPP Bureau - February 16, 2023
Bosentan Tablets for Oral Suspension had annual sales of USD 16 mn in the United States (IQVIA MAT Dec. 2022)
Zydus receives tentative approval from the USFDA for Canagliflozin tablets
By IPP Bureau - February 16, 2023
The drug will be manufactured at the group’s formulation manufacturing facility at Moraiya
Aurobindo Pharma gets VAI classification from USFDA for Telangana plant
By IPP Bureau - February 16, 2023
Company's Unit - IX, an API intermediate facility situated at Sangareddy District, Telangana, has now been classified as Voluntary Action Indicated
Panacea Biotec posts Q3 FY2023 net profit at Rs.19.37 crores
By IPP Bureau - February 16, 2023
The company has reported total income of Rs.129.14 crores during the period ended December 31, 2022 as compared to Rs.157.54 crores during the period ended December 31, 2021.
Thermo Fisher Scientific launches real-time PCR kits for detection of infectious diseases in India
By IPP Bureau - February 15, 2023
The Applied Biosystems TaqPath PCR kits have been analytically- and clinically-validated for use in patient care
Wockhardt registers Q3 FY23 consolidated loss at Rs. 96 Cr
By IPP Bureau - February 15, 2023
The company has reported total income of Rs. 701 crores during the period ended December 31, 2022
ISHIC partners with the DGHS Jammu to bring down the burden of lung cancer in India
By IPP Bureau - February 15, 2023
Qure.ai is scaling-up the integration of its AI-powered chest x-ray interpretation tool that can benefit early and easy detection of lung diseases including lung cancer.
